Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005)

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 2, 2007, Pages 207-215

  Rhomberg, Paul R ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; Carbapenems; Meropenem; MYSTIC program; Surveillance

Indexed keywords

AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG POTENCY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH PROGRAM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; THIENAMYCINS; UNITED STATES;

EID: 33846363598     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.07.009     Document Type: Article

References (36)

1. Arakawa Y., Shibata N., Shibayama K., Kurokawa H., Yagi T., Fujiwara H., and Goto M. Convenient test for screening metallo-β-lactamase-producing gram-negative bacteria by using thiol compounds. J. Clin. Microbiol. 38 (2000) 40-43
2. Biedenbach D.J., Moet G.J., and Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50 (2004) 59-69
3. Bouchillon S.K., Hoban D.J., Johnson B.M., Johnson J.L., Hsiung A., and Dowzicky M.J. In vitro activity of tigecycline against 3,989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 173-179
4. Bradford P.A., Bratu S., Urban C., Visalli M., Mariano N., Landman D., Rahal J.J., Brooks S., Cebular S., and Quale J. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis. 39 (2004) 55-60
5. Brink A.J., Feldman C., Grolman D.C., Muckart D., Pretorius J., Richards G.A., Senekal M., and Sieling W. Appropriate use of the carbapenems. S. Afr. Med. J. 94 (2004) 857-861
6. GIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob. Agents Chemother. 48 (2004) 4654-4661
7. CLSI. Clinical and Laboratory Standards Institute (2006). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved Standards M7-A7 (2006), CLSI, Wayne, PA
8. CLSI. Clinical and Laboratory Standards Institute (2006). Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100-S16 (2006), CLSI, Wayne, PA
9. Cornaglia G., Hryniewicz W., Jarlier V., Kahlmeter G., Mittermayer H., Stratchounski L., and Baquero F. European recommendations for antimicrobial resistance surveillance. Clin. Microbiol. Infect. 10 (2004) 349-383
10. Critchley I.A., Draghi D.C., Sahm D.F., Thornsberry C., Jones M.E., and Karlowsky J.A. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J. Antimicrob. Chemother. 51 (2003) 639-649
11. Felmingham D., White A.R., Jacobs M.R., Appelbaum P.C., Poupard J., Miller L.A., and Gruneberg R.N. The Alexander project: the benefits from a decade of surveillance. J. Antimicrob. Chemother. 56 (2005) ii3-ii21
12. Fridkin S.K., Edwards J.R., Tenover F.C., Gaynes R.P., and McGowan Jr. J.E. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin. Infect. Dis. 33 (2001) 324-330
13. Fritsche T.R., Strabala P.A., Sader H.S., Dowzicky M.J., and Jones R.N. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn. Microbiol. Infect. Dis. 52 (2005) 209-213
14. Gales A.C., Biedenbach D.J., Winokur P., Hacek D.M., Pfaller M.A., and Jones R.N. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagn. Microbiol. Infect. Dis. 39 (2001) 125-127
15. Harding I., and Felmingham D. PROTEKT years 1-3 (1999-2002): study design and methodology. J. Chemother. 16 (2004) 9-18
16. Hoban D., Waites K., and Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn. Microbiol. Infect. Dis. 45 (2003) 251-259
17. Jones R.N. Susceptibility trends in respiratory pathogens: the role of the newer fluoroquinolones. Consultant 44 (2004) S5-S13
18. Jones R.N., and Masterton R. Determining the value of antimicrobial surveillance programs. Diagn. Microbiol. Infect. Dis. 41 (2001) 171-175
19. Jones R.N., and Pfaller M.A. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin. Microbiol. Infect. 9 (2003) 708-712
20. Jones R.N., Ballow C.H., and Biedenbach D.J. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 40 (2001) 59-66
21. KPC-2/3 among clinical strains of Enterobacteriaceae isolated in New York City and other Medical Centers: report from the MYSTIC Program 2005. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Abstr. C2-96 (2005)
22. Kimura S., Alba J., Shiroto K., Sano R., Niki Y., Maesaki S., Akizawa K., Kaku M., Watanuki Y., Ishii Y., and Yamaguchi K. Clonal diversity of metallo-β-lactamase-possessing Pseudomonas aeruginosa in geographically diverse regions of Japan. J. Clin. Microbiol. 43 (2005) 458-461
23. Kollef M.H. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir. Care 49 (2004) 1530-1541
24. Pfaller M.A., Jones R.N., and Biedenbach D.J. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 41 (2001) 177-182
25. Pottumarthy S., Moland E.S., Juretschko S., Swanzy S.R., Thomson K.S., and Fritsche T.R. NMC-A carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg. Infect. Dis. 9 (2003) 999-1002
26. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States 2004. J. Chemother. 17 (2005) 459-469
27. Rossi F., Baquero F., Hsueh P.R., Paterson D.L., Bochicchio G.V., Snyder T.A., Satishchandran V., McCarroll K., Dinubile M.J., and Chow J.W. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Advance Access published online on May 22, 2006. J. Antimicrob. Chemother. (2006) 10.1093/jac/dkl199
28. Sader H.S., Streit J.M., Fritsche T.R., and Jones R.N. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn. Microbiol. Infect. Dis. 50 (2004) 201-204
29. Sader H.S., Deshpande L.M., Fritsche T.R., and Jones R.N. Evaluation of occurrence and characterization of carbapenamases among Enterobacteriaceae isolated by the SENTRY Antimicrobial Surveillance Program worldwide (2000-2004). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Abstr. C2-104 (2005)
30. Sader H.S., Fritsche T.R., and Jones R.N. Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn. Microbiol. Infect. Dis. 52 (2005) 265-273
31. IMP) in gram-negative rods resistant to broad-spectrum β-lactams. J. Clin. Microbiol. 34 (1996) 2909-2913
32. VIM-7, an evolutionarily distinct metallo-β-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 48 (2004) 329-332
33. Toleman M.A., Biedenbach D., Bennett D.M., Jones R.N., and Walsh T.R. Italian metallo-β-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. J. Antimicrob. Chemother. 55 (2005) 61-70
34. Turner P.J. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003). Diagn. Microbiol. Infect. Dis. 50 (2004) 291-293
35. Unal S., and Garcia-Rodriguez J.A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn. Microbiol. Infect. Dis. 53 (2005) 265-271
36. Woodford N., Tierno Jr. P.M., Young K., Tysall L., Palepou M.F., Ward E., Painter R.E., Suber D.F., Shungu D., Silver L.L., Inglima K., Kornblum J., and Livermore D.M. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A b-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. 48 (2004) 4793-4799